GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes management and now some are also licensed for weight management
Individual response varies considerably, and some patients may respond better to one medication than the other
GLP-1 RAs are built on slightly different active ingredients, depending on which brand you get, and semaglutide is the active ingredient for Ozempic and Wegovy
By March 2024, the FDA approved Semaglutide injection (Wegovy) as the first drug to reduce the risk of serious heart disease in obese or overweight adults
Ask the physician to review adherence, dose, storage, injection technique, side effects, other medications, and realistic goals
Ozempic (Semaglutide): Originally developed for type 2 diabetes, Ozempic has proven to be highly effective for appetite reduction and weight control